Elevance Health Declares $1.72 Quarterly Dividend
Elevance Health, Inc. (NYSE: ELV), a major health insurance company, announced a $1.72 per share quarterly dividend for the second quarter of 2026. The payout represents a distribution of $376 million to shareholders.
Elevance Health, Inc. (NYSE: ELV), a health insurance company serving approximately 105 million consumers, declared a quarterly cash dividend of $1.72 per share on April 21, 2026. The Audit Committee of the company's Board of Directors approved the second quarter 2026 distribution. Read more dividend announcements.
The dividend amount remains unchanged from the previous quarterly payment of $1.72 per share, which also totaled $376 million. Elevance Health paid the first quarter dividend alongside repurchasing 3.7 million shares for $1.1 billion at a weighted average price of $304.68.
| Dividend Details | Date |
|---|---|
| Amount Per Share | $1.72 |
| Record Date | June 10, 2026 |
| Payment Date | June 25, 2026 |
| Total Distribution | $376 million |
First Quarter Financial Performance
The company reported operating cash flow of $4.3 billion in the first quarter of 2026, an increase of $3.3 billion year over year. Cash and investments at the parent company totaled approximately $2.2 billion as of March 31, 2026.
As of the end of the first quarter, Elevance Health had approximately $5.6 billion of Board-approved share repurchase authorization remaining.
Business Segment Results
The Health Benefits segment generated operating revenue of $42.5 billion in the first quarter, up 2.6 percent from the prior year quarter. Medical membership stood at approximately 45.4 million as of March 31, 2026, an increase of 186,000 from year-end 2025.
The benefit expense ratio was 86.8 percent, an increase of 40 basis points, reflecting elevated medical cost trends in Medicaid, partially offset by improved performance in Medicare. Days in Claims Payable reached 46.6 days, up 5.3 days from December 31, 2025.
Carelon, the company's pharmacy and services segment, posted operating revenue of $18.0 billion in the first quarter, up 7.9 percent year over year. Growth was driven by the scaling of Carelon Services risk-based solutions and CarelonRx product revenue.
The company recorded a $935 million accrual related to a potential exposure from a CMS notice and a $129 million charge for business optimization initiatives. The adjusted operating expense ratio was 10.5 percent, a decrease of 20 basis points driven by disciplined expense management.